Skip to Main Content


Cure Available for Hepatitis C but Oregon Limits Access

By | Leave a Comment

5 years ago, drugs to treat Hepatitis C called direct-acting retrovirals came out into the market. These drugs had cure rates of more than 90% of Hepatitis C infections. However, due to the costs of the drug, the Oregon Health Plan which is the State’s version of Medicaid limits access to only the sickest individuals.

In January of this year, Oregon’s Medicaid loosened its rules and allowed people with less severe damage or those deemed fibrosis stage two through four to have access. However, stage 1 is still currently denied access contrary to guidelines of health professional groups.


For more information, see:

Thematic Areas:

Comments are closed.

The views reflected in this expert column are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.